Movement Alert｜Rhythm Pharmaceuticals Inc. Intraday Decline 5.13% in Regular Trading, pullback follows takeover-driven surge

Market Focus11-06

On November 6, Rhythm Pharmaceuticals Inc. fell 5.13% in Regular Trading, trading at $104.895/share, with turnover of $317 million.

The latest identifiable catalyst remains takeover-related news: reports said AstraZeneca made an offer of about $10 billion, or $124 per share, for Rhythm Pharmaceuticals Inc., with some reports indicating the proposal could reach as high as $134 per share including milestone-based payments.

The decline appears to reflect a pullback after the prior session's sharp rally on that report. Supporting context includes improving fundamentals: Rhythm Pharmaceuticals Inc. recently reported a third-quarter loss of $0.61 per share, narrower than the expected $0.69 loss, while analysts said Imcivree could exceed $2 billion in worldwide sales by 2030 as the company expands in hypothalamic obesity and rare-disease markets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment